Beta-2 adrenergic agonists: Focus on safety and benefits versus risks

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 246-253

  Ortega, Victor E ^a   Peters, Stephen P ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCUNEB; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; ISOPRENALINE; LONG ACTING DRUG; PERFOROMIST; PIRBUTEROL ACETATE; PLACEBO; PROCATEROL; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; TERBUTALINE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; GLUCOCORTICOID;

ASTHMA; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; HUMAN; LOW DRUG DOSE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; PATHOPHYSIOLOGY; PROCEDURES;

ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; RECEPTORS, ADRENERGIC, BETA-2; ADRENERGIC BETA-2 RECEPTOR AGONISTS;

EID: 77954660610     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.04.009     Document Type: Review

References (37)

1. Bateman E.D., Hurd S.S., Barnes P.J., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178.
2. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844.
3. D'Alonzo G.E., Nathan R.A., Henochowicz S., Morris R.J., Ratner P., Rennard S.I. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994, 271:1412-1416.
4. Greening A.P., Ind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994, 344:219-224.
5. Maesen F.P., Smeets J.J., Gubbelmans H.L., Zweers P.G. Bronchodilator effect of inhaled formoterol vs salbutamol over 12hours. Chest 1990, 97:590-594.
6. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26.
7. Pearlman D.S., Chervinsky P., LaForce C., et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992, 327:1420-1425.
8. Stolley P.D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 1972, 105:883-890.
9. Crane J., Pearce N., Flatt A., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989, 1:917-922.
10. Grainger J., Woodman K., Pearce N., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991, 46:105-111.
11. Pearce N., Grainger J., Atkinson M., et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990, 45:170-175.
12. Pearce N., Beasley R., Crane J., Burgess C., Jackson R. End of the New Zealand asthma mortality epidemic. Lancet 1995, 345:41-44.
13. Pearce N., Burgess C., Crane J., Beasley R. Fenoterol, asthma deaths, and asthma severity. Chest 1997, 112:1148-1150.
14. Spitzer W.O., Buist A.S. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990, 45:645-646.
15. Suissa S., Ernst P., Boivin J.F., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994, 149:604-610.
16. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990, 336:1391-1396.
17. Drazen J.M., Israel E., Boushey H.A., et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996, 335:841-847.
18. Castle W., Fuller R., Hall J., Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993, 306:1034-1037.
19. Salpeter S.R., Buckley N.S., Ormiston T.M., Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006, 144:904-912.
20. Nelson H.S., Dorinsky P.M. Safety of long-acting beta-agonists. Ann Intern Med 2006, 145:706-710.
21. US Food and Drug Administration. FDA Public Health Advisory: Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). 11-18-2005. 6-29-0008. Ref Type: Internet Communication.
22. US Food and Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2-18-2010. Ref Type: Internet Communication.
23. Anderson H.R., Ayres J.G., Sturdy P.M., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005, 330:117.
24. Cates C.J., Cates M.J., Lasserson T.J. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008, CD006923.
25. Cates C.J., Cates M.J. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008, CD006363.
26. Sears M.R., Ottosson A., Radner F., Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009, 33:21-32.
27. Levenson, M: Long-acting beta-agonists and adverse asthma events meta-analysis: statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee on December 10-11, 2008. 3-27-2010. Ref Type: Internet Communication.
28. Kramer J.M. Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 2009, 360:1592-1595.
29. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997, 337:1405-1411.
30. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001, 164:1392-1397.
31. Lazarus S.C., Boushey H.A., Fahy J.V., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583-2593.
32. Lemanske R.F., Sorkness C.A., Mauger E.A., et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001, 285:2594-2603.
33. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
34. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753.
35. Peters S.P., Prenner B.M., Mezzanotte W.S., Martin P., O'Brien C.D. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 2008, 29:499-516.
36. Stempel D.A., Stoloff S.W., Carranza R., Stanford R.H., Ryskina K.L., Legorreta A.P. Adherence to asthma controller medication regimens. Respir Med 2005, 99:1263-1267.
37. Drazen J.M., O'Byrne P.M. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009, 360:1671-1672.